Rocket One Inc. Common Stock (NASDAQ:RKTO) Stock Rating Raised to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Rocket One Inc. Common Stock (NASDAQ:RKTO) from a strong sell rating to a sell rating in a report released on Sunday morning,Wall Street Zen reports.

Separately, Weiss Ratings cut shares of Rocket One Inc. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, October 14th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $5.00.

Rocket One Inc. Common Stock Price Performance

Shares of RKTO opened at $0.55 on Friday. The business’s fifty day moving average is $0.68 and its 200 day moving average is $0.83. Rocket One Inc. Common Stock has a 12-month low of $0.48 and a 12-month high of $2.45. The stock has a market cap of $12.22 million, a P/E ratio of -0.67 and a beta of 0.90.

Rocket One Inc. Common Stock (NASDAQ:RKTO) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.19) EPS for the quarter.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Rocket One Inc. Common Stock stock. Lido Advisors LLC increased its stake in shares of Rocket One Inc. Common Stock (NASDAQ:RKTO) by 100.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,000 shares of the company’s stock after buying an additional 19,500 shares during the quarter. Lido Advisors LLC owned 0.20% of Rocket One Inc. Common Stock worth $33,000 at the end of the most recent quarter. 7.08% of the stock is currently owned by institutional investors and hedge funds.

About Rocket One Inc. Common Stock

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.